BackgroundKaposi's sarcoma continues to be the most common human immunodeficiency virus
- associated neoplasm with considerable morbidity and mortality.ObjectiveTo describe the clinical and laboratory characteristics, initial staging, and
outcomes of aids patients with Kaposi's sarcoma at an university hospital of
Recife, Pernambuco.MethodsThis is a descriptive study with analytic character, retrospective, of a case
series between 2004 and 2014.ResultsOf the 22 patients included in the study, 20 were aged <40 years (72.7%).
The majority had CD4+ T lymphocyte counts of <200 cells/mm3
(77.3%) and human immunodeficiency virus loads of <100,000 copies/mL
(78.9%). Lesions were most commonly observed on the skin (90%), and internal
organs were affected in 11 of the 22 patients. Only 7 (31.8%) of the 22
patients were undergoing antiretroviral therapy (ART) at the time of Kaposis
sarcoma diagnosis, and the initial disease staging classification was high
risk (Aids Clinical Trials Group Oncology Committee) in 19 of the 22
patients (86.4%). Regarding Kaposi's sarcoma treatment, 17 of 22 patients
(77.3%) underwent systemic chemotherapy + ART and 5 were treated exclusively
with ART. Eight of the 22 patients died (36.5%); of these, 87.5% had died
within one year of Kaposi's sarcoma diagnosis.Limitation of the studyWithout a control group, this study cannot be used to generate
hypotheses.ConclusionsDespite the association between aids and late Kaposi's sarcoma diagnosis in
the study population, including an unfavorable risk at the time of staging,
a lower mortality rate was observed relative to other studies; this might be
related to access to a specialized health service.